Other Current Assets	9 Months Ended
Sep. 30, 2021
Other Current Assets
Other Current Assets	4. Other Current Assets As of September 30, 2021, other current assets included prepaid expenses of $1.5 million, comprised primarily of prepayments of $1.0 million made for the Company’s clinical trials for BP1002 in lymphoma, prexigebersen in AML and prexigebersen-A in solid tumors as well as prepaid insurance of $0.4 million and prepaid expenses related to preclinical studies of $0.1 million. As of December 31, 2020, other current assets included prepaid expenses of $0.9 million, comprised primarily of prepayments of $0.6 million made for the Company’s clinical trials for BP1002 in lymphoma and prexigebersen-A in solid tumors as well as prepaid insurance of $0.3 million.

Other Current Assets

9 Months Ended

Sep. 30, 2021

4. Other Current Assets

As of September 30, 2021, other current assets included prepaid expenses of $1.5 million, comprised primarily of prepayments of $1.0 million made for the Company’s clinical trials for BP1002 in lymphoma, prexigebersen in AML and prexigebersen-A in solid tumors as well as prepaid insurance of $0.4 million and prepaid expenses related to preclinical studies of $0.1 million. As of December 31, 2020, other current assets included prepaid expenses of $0.9 million, comprised primarily of prepayments of $0.6 million made for the Company’s clinical trials for BP1002 in lymphoma and prexigebersen-A in solid tumors as well as prepaid insurance of $0.3 million.